Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 5th edition, 486 pages

Free download


  Prostate Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 161 articles:
HTML format



Single Articles


    November 2020
  1. OGASAWARA N, Nakiri M, Kurose H, Ueda K, et al
    Longitudinal Changes in Health-related Quality of Life After (125)I Low-dose-rate Brachytherapy for Localized Prostate Cancer.
    Anticancer Res. 2020;40:6443-6456.
    PubMed     Abstract available


  2. SIVONOVA MK, Jurecekova J, Kaplan P, Hives M, et al
    Association of MDM2 T309G (rs2279744) Polymorphism and Expression Changes With Risk of Prostate Cancer in the Slovak Population.
    Anticancer Res. 2020;40:6257-6264.
    PubMed     Abstract available


  3. BAI L, Li X, Ma X, Zhao R, et al
    In Vitro Effect and Mechanism of Action of Ergot Alkaloid Dihydroergocristine in Chemoresistant Prostate Cancer Cells.
    Anticancer Res. 2020;40:6051-6062.
    PubMed     Abstract available


  4. BUWENGE M, Alitto AR, Cilla S, Capocaccia I, et al
    Simultaneous Integrated Radiotherapy Boost to the Dominant Intraprostatic Lesion: Final Results of a Phase I/II Trial.
    Anticancer Res. 2020;40:6499-6503.
    PubMed     Abstract available


    October 2020
  5. YUNO T, Miyata Y, Matsuo T, Mukae Y, et al
    Relationship Between Stage-specific Embryonic Antigen-4 and Anti-cancer Effects of Neoadjuvant Hormonal Therapy in Prostate Cancer.
    Anticancer Res. 2020;40:5567-5575.
    PubMed     Abstract available


  6. KODITZ B, Fries JWU, GObel H, Paffenholz P, et al
    Mxi-2 Dependent Regulation of p53 in Prostate Cancer.
    Anticancer Res. 2020;40:5539-5544.
    PubMed     Abstract available


  7. MIYASHITA M, Tomogane M, Nakamura Y, Shimizu T, et al
    Sphere-derived Prostate Cancer Stem Cells Are Resistant to gammadelta T Cell Cytotoxicity.
    Anticancer Res. 2020;40:5481-5487.
    PubMed     Abstract available


    September 2020
  8. MINAMI H, Ando Y, Tamura K, Tajima T, et al
    Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer.
    Anticancer Res. 2020;40:5229-5235.
    PubMed     Abstract available


  9. ISHII A, Shigemura K, Kitagawa K, Sung SY, et al
    Anti-tumor Effect of Hedgehog Signaling Inhibitor, Vismodegib, on Castration-resistant Prostate Cancer.
    Anticancer Res. 2020;40:5107-5114.
    PubMed     Abstract available


  10. MIYAO T, Koike H, Sekine Y, Ohtsu A, et al
    YM155 Reverses Cabazitaxel Resistance in Castration-resistant Prostate Cancer by Reducing Survivin Expression.
    Anticancer Res. 2020;40:5091-5095.
    PubMed     Abstract available


    August 2020
  11. BUWENGE M, Deodato F, Dominsky N, Ntreta M, et al
    Radiotherapy of Prostate Carcinoma: A Comparison of the Predictive Role of EAU Versus NCCN Risk Stratification Systems.
    Anticancer Res. 2020;40:4413-4418.
    PubMed     Abstract available


  12. SHIMURA Y, Suga Y, Itai S, Iwamoto H, et al
    Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer.
    Anticancer Res. 2020;40:4291-4297.
    PubMed     Abstract available


    July 2020
  13. LIAO PC, Hung SC, Hu JC, Chiu KY, et al
    Retzius-sparing Robotic-assisted Radical Prostatectomy Facilitates Early Continence Regardless of Neurovascular Bundle Sparing.
    Anticancer Res. 2020;40:4075-4080.
    PubMed     Abstract available


    June 2020
  14. SUZUKI K, Terakawa T, Jimbo N, Inaba R, et al
    Clinical Features of Treatment-related Neuroendocrine Prostate Cancer: A Case Series.
    Anticancer Res. 2020;40:3519-3526.
    PubMed     Abstract available


  15. KODIYAN J, Ashamalla M, Guirguis A, Ashamalla H, et al
    Race Does Not Affect Survival in Patients With Prostate Cancer Treated With Radiation Therapy.
    Anticancer Res. 2020;40:3307-3314.
    PubMed     Abstract available


    May 2020
  16. OU YC, Chang KH, Tung MC, Tsai IJ, et al
    Building a Nomogram for Prediction of Prostate Cancer in Patients With Preoperatively Suspected Prostate Cancer.
    Anticancer Res. 2020;40:2995-3002.
    PubMed     Abstract available


  17. HAN Q, Tan Y, Hoffman RM
    Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient.
    Anticancer Res. 2020;40:2813-2819.
    PubMed     Abstract available


  18. WANG S, Tailor K, Kwabi-Addo B
    Androgen-induced Epigenetic Profiles of Polycomb and Trithorax Genes in Prostate Cancer Cells.
    Anticancer Res. 2020;40:2559-2565.
    PubMed     Abstract available


  19. ZHANG B, Leech M
    A Review of Stereotactic Body Radiation Therapy in the Management of Oligometastatic Prostate Cancer.
    Anticancer Res. 2020;40:2419-2428.
    PubMed     Abstract available


    April 2020
  20. OVCARICEK PP, Frobe A, Verburg FA, Murgic J, et al
    Association of Triiodothyronine Levels With Prostate Cancer Histopathological Differentiation and Tumor Stage.
    Anticancer Res. 2020;40:2323-2329.
    PubMed     Abstract available


  21. NAKANO T, Kadono Y, Iwamoto H, Yaegashi H, et al
    Therapeutic Effect of Ethinylestradiol in Castration-resistant Prostate Cancer.
    Anticancer Res. 2020;40:2291-2296.
    PubMed     Abstract available


  22. NAKAMURA R, Hirata T, Suzuki O, Otani K, et al
    Stereotactic Body Radiotherapy Using CyberKnife(R) for Localized Low- and Intermediate-risk Prostate Cancer: Initial Report on a Phase I/II Trial.
    Anticancer Res. 2020;40:2053-2057.
    PubMed     Abstract available


  23. MASIUK M, Lewandowska M, Dobak E, Urasinska E, et al
    Nucleolin and Nucleophosmin Expression in Gleason 3 and Gleason 4 Prostate Cancer With Seminal Vesicles Invasion (pT3b).
    Anticancer Res. 2020;40:1973-1979.
    PubMed     Abstract available


    March 2020
  24. NGUYEN T, Bartscht T, Schild SE, Rades D, et al
    Performance Status Is Associated With Survival in Elderly Patients Irradiated for Cerebral Metastases from Prostate Cancer.
    Anticancer Res. 2020;40:1665-1668.
    PubMed     Abstract available


  25. VIDAL AC, Duong F, Howard LE, Wiggins E, et al
    Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer.
    Anticancer Res. 2020;40:1459-1462.
    PubMed     Abstract available


  26. PLOSKONOS MV, Syatkin SP, Neborak EV, Hilal A, et al
    Polyamine Analogues of Propanediamine Series Inhibit Prostate Tumor Cell Growth and Activate the Polyamine Catabolic Pathway.
    Anticancer Res. 2020;40:1437-1441.
    PubMed     Abstract available


  27. UCHIDA H, Hirata T, Otani K, Suzuki O, et al
    Assessment of Daily Replanning and Geometrical Variation of High-dose-rate Brachytherapy for the Prostate.
    Anticancer Res. 2020;40:1677-1682.
    PubMed     Abstract available


    February 2020
  28. MIYAKE H, Watanabe K, Matsushita Y, Watanabe H, et al
    Assessment of Factors Predicting Disease Progression in Japanese Patients With Non-Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2020;40:1101-1106.
    PubMed     Abstract available


  29. XOXAKOS I, Petraki C, Msauel P, Armakolas A, et al
    Expression of Kisspeptin (KISS1) and its Receptor GPR54 (KISS1R) in Prostate Cancer.
    Anticancer Res. 2020;40:709-718.
    PubMed     Abstract available


    January 2020
  30. SHIOTA M, Nakamura M, Yokomizo A, Tomoda T, et al
    Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel.
    Anticancer Res. 2020;40:335-339.
    PubMed     Abstract available


  31. ABBAS M, Mason T, Ibad A, Khraiwesh M, et al
    Genetic Polymorphisms in IL-10 Promoter Are Associated With Smoking and Prostate Cancer Risk in African Americans.
    Anticancer Res. 2020;40:27-34.
    PubMed     Abstract available


    November 2019
  32. BUWENGE M, Deodato F, Macchia G, Siepe G, et al
    Radiotherapy Plus GnRH Analogue Versus High Dose Bicalutamide: A Case Control Study.
    Anticancer Res. 2019;39:6373-6378.
    PubMed     Abstract available


  33. KUROSE H, Ueda K, Kondo R, Ogasawara S, et al
    Elevated Expression of EPHA2 Is Associated With Poor Prognosis After Radical Prostatectomy in Prostate Cancer.
    Anticancer Res. 2019;39:6249-6257.
    PubMed     Abstract available


  34. APPREY V, Wang S, Tang W, Kittles RA, et al
    Association of Genetic Ancestry With DNA Methylation Changes in Prostate Cancer Disparity.
    Anticancer Res. 2019;39:5861-5866.
    PubMed     Abstract available


    October 2019
  35. YASUOKA S, Yuasa T, Ogawa M, Komai Y, et al
    Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan.
    Anticancer Res. 2019;39:5803-5809.
    PubMed     Abstract available


  36. TAKEMURA K, Ito M, Nakanishi Y, Kataoka M, et al
    Serum gamma-Glutamyltransferase as a Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide.
    Anticancer Res. 2019;39:5773-5780.
    PubMed     Abstract available


  37. MAGNIFICO MC, Macone A, Marani M, Bouzidi A, et al
    Linking Infection and Prostate Cancer Progression: Toll-like Receptor3 Stimulation Rewires Glucose Metabolism in Prostate Cells.
    Anticancer Res. 2019;39:5541-5549.
    PubMed     Abstract available


  38. INAMURA SO, Ito H, Taga M, Tsuchiyama K, et al
    Low-dose Docetaxel Enhanced the Anticancer Effect of Temsirolimus by Overcoming Autophagy in Prostate Cancer Cells.
    Anticancer Res. 2019;39:5417-5425.
    PubMed     Abstract available


  39. KAIKKONEN E, Ettala O, Nikulainen I, Taimen P, et al
    ANO7 rs77559646 Is Associated With First-line Docetaxel Treatment Response in Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2019;39:5353-5359.
    PubMed     Abstract available


  40. MOKBEL K, Wazir U, Mokbel K
    Chemoprevention of Prostate Cancer by Natural Agents: Evidence from Molecular and Epidemiological Studies.
    Anticancer Res. 2019;39:5231-5259.
    PubMed     Abstract available


  41. DART DA, Koushyar S, Lanning BE, Jiang W, et al
    MiR-221 Is Specifically Elevated in PC3 Cells and its Deletion Reduces Adhesion, Motility and Growth.
    Anticancer Res. 2019;39:5311-5327.
    PubMed     Abstract available


    September 2019
  42. ZAMAGNI A, Buwenge M, Macchia G, Siepe G, et al
    Accelerated Middle Half Body Radiotherapy in Bone Metastases from Prostate Cancer: A Phase I Study (SHARON Project).
    Anticancer Res. 2019;39:5065-5069.
    PubMed     Abstract available


  43. TAKAGI H, Ii H, Kageyama S, Hanada E, et al
    Blockade of gamma-Glutamylcyclotransferase Enhances Docetaxel Growth Inhibition of Prostate Cancer Cells.
    Anticancer Res. 2019;39:4811-4816.
    PubMed     Abstract available


    August 2019
  44. SHIOTA M, Nakamura M, Yokomizo A, Tomoda T, et al
    Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study.
    Anticancer Res. 2019;39:4411-4414.
    PubMed     Abstract available


  45. SINHA AA
    Electron Microscopic Analysis of Stem Cells in Human Prostate Cancer, Including Inverted Capsule Embedding Methods for Archival Sections and Falcon Films for Prostate Cancer Cell Lines.
    Anticancer Res. 2019;39:4171-4177.
    PubMed     Abstract available


  46. STANZIONE A, Ponsiglione A, Cuocolo R, Cocozza S, et al
    Abbreviated Protocols versus Multiparametric MRI for Assessment of Extraprostatic Extension in Prostatic Carcinoma: A Multireader Study.
    Anticancer Res. 2019;39:4449-4454.
    PubMed     Abstract available


    July 2019
  47. CHANG LW, Hung SC, Wang SS, Li JR, et al
    Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.
    Anticancer Res. 2019;39:3901-3908.
    PubMed     Abstract available


  48. CASTRO MJ, Careaga VP, Sacca PA, Faraoni MB, et al
    Lupane Triterpenoids and New Derivatives as Antiproliferative Agents Against Prostate Cancer Cells.
    Anticancer Res. 2019;39:3835-3845.
    PubMed     Abstract available


  49. MAEHANA S, Matsumoto Y, Kojima F, Kitasato H, et al
    Interleukin-24 Transduction Modulates Human Prostate Cancer Malignancy Mediated by Regulation of Anchorage Dependence.
    Anticancer Res. 2019;39:3719-3725.
    PubMed     Abstract available


  50. CROWLEY E, Rowan NJ, Faller D, Friel AM, et al
    Natural and Synthetic Isothiocyanates Possess Anticancer Potential Against Liver and Prostate Cancer In Vitro.
    Anticancer Res. 2019;39:3469-3485.
    PubMed     Abstract available


  51. YAMAGUCHI N, Morizane S, Yumioka T, Iwamoto H, et al
    Flutamide as an Alternative Anti-androgen Agent and Predictor of the Efficacy of Novel Androgen Receptor-targeted Agents.
    Anticancer Res. 2019;39:3879-3885.
    PubMed     Abstract available


    June 2019
  52. KOBAYASHI T, Namitome R, Hirata YU, Shiota M, et al
    Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With De Novo Metastatic Prostate Cancer.
    Anticancer Res. 2019;39:3191-3195.
    PubMed     Abstract available


  53. DRUDI FM, Cantisani V, Angelini F, Ciccariello M, et al
    Multiparametric MRI Versus Multiparametric US in the Detection of Prostate Cancer.
    Anticancer Res. 2019;39:3101-3110.
    PubMed     Abstract available


  54. ITO T, Kanao K, Takahara K, Ando R, et al
    Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2019;39:3089-3094.
    PubMed     Abstract available


  55. DROBKOVA H, Jurecekova J, Sivonova MK, Mazuchova J, et al
    Associations Between Gene Polymorphisms of Vascular Endothelial Growth Factor and Prostate Cancer.
    Anticancer Res. 2019;39:2903-2909.
    PubMed     Abstract available


  56. HU M, Tang Y, Long G, Zhang D, et al
    Primary Extracranial Meningioma of Mastoid in a Patient With History of Skin Squamous Cell Carcinoma, Lung Adenocarcinoma and Prostatic Carcinoma.
    Anticancer Res. 2019;39:3197-3201.
    PubMed     Abstract available


    May 2019
  57. KADOMOTO S, Yaegashi H, Nakashima K, Iijima M, et al
    Quantification of Bone Metastasis of Castration-resistant Prostate Cancer After Enzalutamide and Abiraterone Acetate Using Bone Scan Index on Bone Scintigraphy.
    Anticancer Res. 2019;39:2553-2559.
    PubMed     Abstract available


  58. BECKER DJ, Iyengar AD, Punekar SR, Ng J, et al
    Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression.
    Anticancer Res. 2019;39:2467-2473.
    PubMed     Abstract available


  59. DUDZIK P, Trojan SE, Ostrowska B, Zemanek G, et al
    The Epigenetic Modifier 5-Aza-2-deoxycytidine Triggers the Expression of CD146 Gene in Prostate Cancer Cells.
    Anticancer Res. 2019;39:2395-2403.
    PubMed     Abstract available


  60. NAKASHIMA K, Makino T, Kadomoto S, Iwamoto H, et al
    Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital.
    Anticancer Res. 2019;39:2607-2614.
    PubMed     Abstract available


    March 2019
  61. PEPE P, Pennisi M
    Prostate Cancer Diagnosis and Management Across Twenty Years of Clinical Practice: A Single-center Experience on 2,500 Cases.
    Anticancer Res. 2019;39:1397-1401.
    PubMed     Abstract available


  62. MIYAKE H, Matsushita Y, Watanabe H, Tamura K, et al
    Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer.
    Anticancer Res. 2019;39:1391-1396.
    PubMed     Abstract available


    February 2019
  63. KUROSE H, Ueda K, Kondo R, Ogasawara S, et al
    Low-molecular-weight Protein Tyrosine Phosphatase Is a Possible Biomarker for Predicting Postoperative Biochemical Recurrence in Prostate Cancer With Negative Surgical Margins.
    Anticancer Res. 2019;39:957-964.
    PubMed     Abstract available


  64. VAN HALTEREN HK, Vreugdenhil G
    Age Adjusted Charlson Comorbidity Index Strongly Influences Survival, Irrespective of Performance Status and Age, in Patients With Advanced Prostatic Cancer Treated With Enzalutamide.
    Anticancer Res. 2019;39:863-866.
    PubMed     Abstract available


  65. JANOUSEK J, Barta P, Novy Z, Zilkova K, et al
    Antiangiogenic Human Monoclonal Antibody Ramucirumab Radiolabelling: In Vitro Evaluation on VEGFR2-positive Cell Lines.
    Anticancer Res. 2019;39:735-744.
    PubMed     Abstract available


    January 2019
  66. MAKINO T, Nakashima K, Iijima M, Kawaguchi S, et al
    Health-related Quality of Life and Toxicity After Single-fraction High-dose-rate Brachytherapy With External Beam Radiotherapy for Localized and Locally Advanced Prostate Cancer.
    Anticancer Res. 2019;39:477-486.
    PubMed     Abstract available


  67. NIEDER C, Haukland E, Mannsaker B, Pawinski A, et al
    Initiation of Systemic Therapy During the Last 30 Days of Life in Patients With Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2019;39:335-340.
    PubMed     Abstract available


  68. BASS R, Roberto D, Wang DZ, Cantu FP, et al
    Combining Desmopressin and Docetaxel for the Treatment of Castration-Resistant Prostate Cancer in an Orthotopic Model.
    Anticancer Res. 2019;39:113-118.
    PubMed     Abstract available


  69. LI JR, Wang SS, Lin CH, DE Groat WC, et al
    Positive Association of Male Overactive Bladder Symptoms and Androgen Deprivation: A Nationwide Population-based Cohort Study.
    Anticancer Res. 2019;39:305-311.
    PubMed     Abstract available


    December 2018
  70. HAN KY, Chen PN, Hong MC, Hseu YC, et al
    Naringenin Attenuated Prostate Cancer Invasion via Reversal of Epithelial-to-Mesenchymal Transition and Inhibited uPA Activity.
    Anticancer Res. 2018;38:6753-6758.
    PubMed     Abstract available


    November 2018
  71. KOH M, Kim YS, Ahn H, Kim CS, et al
    Patterns of Recurrence After Salvage Radiotherapy Encompassing Pelvic Lymphatics in Men with High-risk Prostate Cancer.
    Anticancer Res. 2018;38:6579-6584.
    PubMed     Abstract available


  72. CHO SY, Kang S, Kim DS, Na HJ, et al
    HSP27, ALDH6A1 and Prohibitin Act as a Trio-biomarker to Predict Survival in Late Metastatic Prostate Cancer.
    Anticancer Res. 2018;38:6551-6560.
    PubMed     Abstract available


  73. HEATH EI, Heilbrun LK, Smith D, Schopperle WM, et al
    Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate Cancer.
    Anticancer Res. 2018;38:6361-6366.
    PubMed     Abstract available


  74. SAK K, Lust H, Kase M, Saar M, et al
    Suppression of Taxanes Cytotoxicity by Citrus Flavonoid Hesperetin in PPC-1 Human Prostate Cancer Cells.
    Anticancer Res. 2018;38:6209-6215.
    PubMed     Abstract available


  75. WANG C, Sargsyan D, Zhang C, Wu R, et al
    Transcriptomic Analysis of Histone Methyltransferase Setd7 Knockdown and Phenethyl Isothiocyanate in Human Prostate Cancer Cells.
    Anticancer Res. 2018;38:6069-6083.
    PubMed     Abstract available


  76. FUJIMURA T, Fukuhara H, Yamada Y, Taguchi S, et al
    Aggressive Cancer Behavior of Latent Gleason Pattern 5 in Prostatectomy Specimens.
    Anticancer Res. 2018;38:6529-6535.
    PubMed     Abstract available


  77. GIACINTI S, Poti G, Roberto M, Macrini S, et al
    Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC.
    Anticancer Res. 2018;38:6029-6039.
    PubMed     Abstract available


    October 2018
  78. HAMA Y, Kaji T
    Long-term Follow-up Results of CT-guided Daily Adaptive Radiation Therapy for Localized Prostate Cancer.
    Anticancer Res. 2018;38:5959-5962.
    PubMed     Abstract available


  79. SUZUKI K, Sakamoto M, Terakawa T, Furukawa J, et al
    Serum DHEA-S Is a Predictive Parameter of Abiraterone Acetate in Patients with Castration-resistant Prostate Cancer.
    Anticancer Res. 2018;38:5929-5935.
    PubMed     Abstract available


  80. SINHA AA, Wilson MJ
    Identification of Two Types of Stem Cells in Methylene Blue-stained Sections of Untreated and Diethylstilbestrol-treated Human Prostate Cancer and Their Characterization by Immunogold Localization of CD133.
    Anticancer Res. 2018;38:5725-5732.
    PubMed     Abstract available


    September 2018
  81. HUNG SC, Wang SS, Li JR, Chen MC, et al
    Outcome of Patients with Metastatic Castration-resistant Prostate Cancer After PSA Progression with Abiraterone Acetate.
    Anticancer Res. 2018;38:5429-5436.
    PubMed     Abstract available


  82. PONTI G, Maccaferri M, Micali S, Manfredini M, et al
    Seminal Cell Free DNA Concentration Levels Discriminate Between Prostate Cancer and Benign Prostatic Hyperplasia.
    Anticancer Res. 2018;38:5121-5125.
    PubMed     Abstract available


  83. NAM RK, Wallis CJD, Amemiya Y, Benatar T, et al
    Identification of a Novel MicroRNA Panel Associated with Metastasis Following Radical Prostatectomy for Prostate Cancer.
    Anticancer Res. 2018;38:5027-5034.
    PubMed     Abstract available


  84. ONISHI T, Sekito S, Terabe T, Shibahara T, et al
    A Combination of Findings Obtained from Pre- and Postoperative Imaging Predict Recovery of Urinary Continence After Non-nerve-sparing Laparoscopic Radical Prostatectomy.
    Anticancer Res. 2018;38:5525-5530.
    PubMed     Abstract available


  85. DADHANIA S, Alonzi R, Douglas S, Gogbashian A, et al
    Single-centre Experience of Use of Radium 223 with Clinical Outcomes Based on Number of Cycles and Bone Marrow Toxicity.
    Anticancer Res. 2018;38:5423-5427.
    PubMed     Abstract available


    August 2018
  86. LIU W, Zhang D, Tan SA, Liu X, et al
    Sigmoid Colon Adenocarcinoma with Isolated Loss of PMS2 Presenting in a Patient with Synchronous Prostate Cancer with Intact MMR: Diagnosis and Analysis of the Family Pedigree.
    Anticancer Res. 2018;38:4847-4852.
    PubMed     Abstract available


  87. MOCHIZUKI K, Kawai M, Odate T, Tahara I, et al
    Diagnostic Utility of Prostein, Uroplakin II and SATB2 for Diagnosing Carcinoma of Unknown Primary Origin: A Systematic Immunohistochemical Profiling.
    Anticancer Res. 2018;38:4759-4766.
    PubMed     Abstract available


    July 2018
  88. TAMARI K, Oh RJ, Masai N, Shiomi H, et al
    Long-term Outcomes of Radiotherapy Regimen of 72 Gy in 30 Fractions for Prostate Cancer.
    Anticancer Res. 2018;38:4207-4212.
    PubMed     Abstract available


  89. MIYAKE H, Matsushita Y, Watanabe H, Tamura K, et al
    Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel.
    Anticancer Res. 2018;38:4179-4185.
    PubMed     Abstract available


  90. MURAKAMI T, Obata H, Akitake N, Shiota M, et al
    Prognostic and Predictive Factors for Anti-androgen Withdrawal in Castration-resistant Prostate Cancer.
    Anticancer Res. 2018;38:4115-4121.
    PubMed     Abstract available


  91. LIAO CH, Wu HC, Hu PS, Hsu SW, et al
    The Association of Matrix Metalloproteinase-1 Promoter Polymorphisms with Prostate Cancer in Taiwanese Patients.
    Anticancer Res. 2018;38:3907-3911.
    PubMed     Abstract available


  92. LEIGHTON X, Bera A, Eidelman O, Eklund M, et al
    High ANXA7 Potentiates Eucalyptol Toxicity in Hormone-refractory Prostate Cancer.
    Anticancer Res. 2018;38:3831-3842.
    PubMed     Abstract available


  93. FERDA J, Ferdova E, Baxa J, Finek J, et al
    (18)F-Fluorocholine PET/MRI in Restaging of Prostatic Carcinoma in Relation to PSA Level and Detection of Active Disease.
    Anticancer Res. 2018;38:4139-4143.
    PubMed     Abstract available


    June 2018
  94. JURECEKOVA J, Drobkova H, Sarlinova M, Babusikova E, et al
    The Role of Interleukin-6 Polymorphism (rs1800795) in Prostate Cancer Development and Progression.
    Anticancer Res. 2018;38:3663-3667.
    PubMed     Abstract available


  95. ACUNA UM, Mo S, Zi J, Orjala J, et al
    Hapalindole H Induces Apoptosis as an Inhibitor of NF-kB and Affects the Intrinsic Mitochondrial Pathway in PC-3 Androgen-insensitive Prostate Cancer Cells.
    Anticancer Res. 2018;38:3299-3307.
    PubMed     Abstract available


  96. VARGA L, Koszo RL, Fodor E, Cserhati A, et al
    Daily Setup Accuracy, Side-effects and Quality of Life During and After Prone Positioned Prostate Radiotherapy.
    Anticancer Res. 2018;38:3699-3705.
    PubMed     Abstract available


  97. TRIGGIANI L, Colosini A, Buglione M, Pasinetti N, et al
    Exploring the Role of Enzalutamide in Combination with Radiation Therapy: An In Vitro Study.
    Anticancer Res. 2018;38:3487-3492.
    PubMed     Abstract available


  98. POSFAI B, Kuthi L, Varga L, Laczo I, et al
    The Colorful Palette of Neuroendocrine Neoplasms in the Genitourinary Tract.
    Anticancer Res. 2018;38:3243-3254.
    PubMed     Abstract available


    May 2018
  99. MARVASO G, Viola A, Fodor C, Jereczek-Fossa BA, et al
    Radiotherapy Plus Total Androgen Block Versus Radiotherapy Plus LHRH Analog Monotherapy for Non-metastatic Prostate Cancer.
    Anticancer Res. 2018;38:3139-3143.
    PubMed     Abstract available


  100. PASQUALETTI F, Panichi M, Sainato A, Baldaccini D, et al
    Image-guided Stereotactic Body Radiotherapy in Metastatic Prostate Cancer.
    Anticancer Res. 2018;38:3119-3122.
    PubMed     Abstract available


  101. OWARI T, Miyake M, Nakai Y, Morizawa Y, et al
    A Genitourinary Cancer-specific Scoring System for the Prediction of Survival in Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma.
    Anticancer Res. 2018;38:3097-3103.
    PubMed     Abstract available


  102. PORPIGLIA F, DE Luca S, Checcucci E, Garrou D, et al
    Comparing Image-guided targeted Biopsies to Radical Prostatectomy Specimens for Accurate Characterization of the Index Tumor in Prostate Cancer.
    Anticancer Res. 2018;38:3043-3047.
    PubMed     Abstract available


  103. TRAMACERE F, Arcangeli S, Pignatelli A, Bracci S, et al
    Postoperative Hypofractionated Radiotherapy for Prostate Cancer.
    Anticancer Res. 2018;38:2951-2956.
    PubMed     Abstract available


    April 2018
  104. UMEZAWA R, Inaba K, Nakamura S, Wakita A, et al
    Long-term Results of External Beam Radiotherapy for Prostate Cancer with Prostate-specific Antigen of More Than 50 ng/ml and Without Evidence of Lymph Node or Distant Metastasis.
    Anticancer Res. 2018;38:2303-2309.
    PubMed     Abstract available


  105. TAKEZAWA Y, Izumi K, Machioka K, Iwamoto H, et al
    Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells.
    Anticancer Res. 2018;38:2045-2055.
    PubMed     Abstract available


  106. MASCAN B, Marignol L
    Aspirin in the Management of Patients with Prostate Cancer Undergoing Radiotherapy: Friend or Foe?
    Anticancer Res. 2018;38:1897-1902.
    PubMed     Abstract available


  107. PEPE P, Pepe G, Pepe L, Garufi A, et al
    Cost-effectiveness of Multiparametric MRI in 800 Men Submitted to Repeat Prostate Biopsy: Results of a Public Health Model.
    Anticancer Res. 2018;38:2395-2398.
    PubMed     Abstract available


    March 2018
  108. ZUGOR V, VON Brandenstein M, Akbarov I, Porres D, et al
    Preoperative Stating of Pelvic Lymph Nodes in Prostate Cancer Patients via Endorectal Magnetic Resonance Imaging.
    Anticancer Res. 2018;38:1763-1765.
    PubMed     Abstract available


  109. VALERIANI M, Bonfili P, Reverberi C, Marinelli L, et al
    Moderate Hypofractionation in Patients with Low-risk Prostate Cancer: Long-term Outcomes.
    Anticancer Res. 2018;38:1671-1676.
    PubMed     Abstract available


  110. GUO J, Yang J, Zhang X, Feng X, et al
    A Panel of Biomarkers for Diagnosis of Prostate Cancer Using Urine Samples.
    Anticancer Res. 2018;38:1471-1477.
    PubMed     Abstract available


  111. KANEKO S, Sato C, Shiozawa N, Sato A, et al
    Suppressive Effect of Delta-Tocotrienol on Hypoxia Adaptation of Prostate Cancer Stem-like Cells.
    Anticancer Res. 2018;38:1391-1399.
    PubMed     Abstract available


  112. LINNEY H, Barrett S
    Stereotactic Body Radiation Therapy for Patients with Early-stage Prostate Cancer.
    Anticancer Res. 2018;38:1231-1240.
    PubMed     Abstract available


  113. SIEPE G, Buwenge M, Nguyen NP, Macchia G, et al
    Postoperative Hypofractionated Radiation Therapy in Prostate Carcinoma: A Systematic Review.
    Anticancer Res. 2018;38:1221-1230.
    PubMed     Abstract available


  114. HOLMBERG AR, Marquez M, Lennartsson L, Meurling L, et al
    Synthesis and Binding of a Novel PSMA-specific Conjugate.
    Anticancer Res. 2018;38:1531-1537.
    PubMed     Abstract available


    February 2018
  115. CHENG WL, Huang CY, Tai CJ, Chang YJ, et al
    Maspin Enhances the Anticancer Activity of Curcumin in Hormone-refractory Prostate Cancer Cells.
    Anticancer Res. 2018;38:863-870.
    PubMed     Abstract available


  116. TANADINI-LANG S, Bogowicz M, Veit-Haibach P, Huellner M, et al
    Exploratory Radiomics in Computed Tomography Perfusion of Prostate Cancer.
    Anticancer Res. 2018;38:685-690.
    PubMed     Abstract available


  117. NIEDER C, Kampe TA, Engljahringer K
    Does Patient-reported Dyspnea Reflect Thoracic Disease Characteristics in Patients with Incurable Cancer?
    Anticancer Res. 2018;38:901-904.
    PubMed     Abstract available


    January 2018
  118. SERTDEMIR M, Weidner AM, Schoenberg SO, Morelli JN, et al
    Is There a Role for Functional MRI for the Assessment of Extracapsular Extension in Prostate Cancer?
    Anticancer Res. 2018;38:427-432.
    PubMed     Abstract available


  119. SASAKI N, Yamazaki H, Shimizu D, Suzuki G, et al
    Long-term Outcomes of a Dose-reduction Trial to Decrease Late Gastrointestinal Toxicity in Patients with Prostate Cancer Receiving Soft Tissue-matched Image-guided Intensity-modulated Radiotherapy.
    Anticancer Res. 2018;38:385-391.
    PubMed     Abstract available


  120. HERNROTH B, Holm I, Gondikas A, Tassidis H, et al
    Manganese Inhibits Viability of Prostate Cancer Cells.
    Anticancer Res. 2018;38:137-145.
    PubMed     Abstract available


  121. MICHALSKA M, Schultze-Seemann S, Kuckuck I, Wolf P, et al
    In Vitro Evaluation of Humanized/De-immunized Anti-PSMA Immunotoxins for the Treatment of Prostate Cancer.
    Anticancer Res. 2018;38:61-69.
    PubMed     Abstract available


  122. CHANG LW, Hung SC, Hu JC, Chiu KY, et al
    Retzius-sparing Robotic-assisted Radical Prostatectomy Associated with Less Bladder Neck Descent and Better Early Continence Outcome.
    Anticancer Res. 2018;38:345-351.
    PubMed     Abstract available


    December 2017
  123. LAMB DS, Sondhauss S, Dunne JC, Woods L, et al
    Proteins Annexin A2 and PSA in Prostate Cancer Biopsies Do Not Predict Biochemical Failure.
    Anticancer Res. 2017;37:6943-6946.
    PubMed     Abstract available


  124. HOFFMANN MA, Taymoorian K, Ruf C, Gerhards A, et al
    Diagnostic Performance of Multiparametric Magnetic Resonance Imaging and Fusion Targeted Biopsy to Detect Significant Prostate Cancer.
    Anticancer Res. 2017;37:6871-6877.
    PubMed     Abstract available


  125. MAYER MJ, Klotz LH, Venkateswaran V
    Evaluating Metformin as a Potential Chemosensitizing Agent when Combined with Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Cells.
    Anticancer Res. 2017;37:6601-6607.
    PubMed     Abstract available


  126. HAGELGANS A, Jandeck C, Friedemann M, Donchin A, et al
    Identification of CpG Sites of SERPINA5 Promoter with Opposite Methylation Patterns in Benign and Malignant Prostate Cells.
    Anticancer Res. 2017;37:6609-6618.
    PubMed     Abstract available


    November 2017
  127. YANG Y, Li X, Mamouni K, Kucuk O, et al
    Mifepristone Has Limited Activity to Enhance the In Vivo Efficacy of Docetaxel and Enzalutamide Against Bone Metastatic and Castration-Resistant Prostate Cancer.
    Anticancer Res. 2017;37:6235-6243.
    PubMed     Abstract available


  128. MUSA MA, Latinwo LM, Joseph MY, Badisa VL, et al
    Identification of 7,8-Diacetoxy-3-Arylcoumarin Derivative as a Selective Cytotoxic and Apoptosis-inducing Agent in a Human Prostate Cancer Cell Line.
    Anticancer Res. 2017;37:6005-6014.
    PubMed     Abstract available


    October 2017
  129. SHIMIZU D, Yamazaki H, Nishimura T, Aibe N, et al
    Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided Intensity-modulated Radiotherapy.
    Anticancer Res. 2017;37:5829-5835.
    PubMed     Abstract available


  130. MACCHIA G, Siepe G, Capocaccia I, Nguyen NP, et al
    Hypofractionated Postoperative IMRT in Prostate Carcinoma: A Phase I/II Study.
    Anticancer Res. 2017;37:5821-5828.
    PubMed     Abstract available


  131. IWAMA K, Yamazaki H, Shimizu D, Suzuki G, et al
    Interfractional Rectal Displacement Requiring Repeated Precaution Did Not Correlate to Biochemical Control and Rectal Toxicity in Patients with Prostate Cancer Treated with Image-guided Intensity-modulated Radiation Therapy.
    Anticancer Res. 2017;37:5755-5760.
    PubMed     Abstract available


  132. OBATA H, Shiota M, Akitake N, Takeuchi A, et al
    Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
    Anticancer Res. 2017;37:5631-5637.
    PubMed     Abstract available


  133. IZUMI K, Shigehara K, Nohara T, Narimoto K, et al
    Both High and Low Serum Total Testosterone Levels Indicate Poor Prognosis in Patients with Prostate Cancer.
    Anticancer Res. 2017;37:5559-5564.
    PubMed     Abstract available


  134. HUTCHINSON J, Marignol L
    Clinical Potential of Statins in Prostate Cancer Radiation Therapy.
    Anticancer Res. 2017;37:5363-5372.
    PubMed     Abstract available


    September 2017
  135. VON HARDENBERG J, Schwartz M, Werner T, Fuxius S, et al
    Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel.
    Anticancer Res. 2017;37:5117-5124.
    PubMed     Abstract available


  136. WU X, Reinikainen P, Kapanen M, Vierikko T, et al
    Diffusion-weighted MRI Provides a Useful Biomarker for Evaluation of Radiotherapy Efficacy in Patients with Prostate Cancer.
    Anticancer Res. 2017;37:5027-5032.
    PubMed     Abstract available


  137. ORYWAL K, Jelski W, Werel T, Szmitkowski M, et al
    The Diagnostic Significance of Serum Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in Prostate Cancer Patients.
    Anticancer Res. 2017;37:4961-4965.
    PubMed     Abstract available


  138. WIKSTROM J, Isacsson U, Johansson B, Lennernas BO, et al
    Magnetic Resonance Compatibility of a Transponder Aimed for Radiotherapy Positioning - A Phantom Study.
    Anticancer Res. 2017;37:4993-4996.
    PubMed     Abstract available


    August 2017
  139. YU S, Jiang Y, Wan F, Wu J, et al
    Immortalized Cancer-associated Fibroblasts Promote Prostate Cancer Carcinogenesis, Proliferation and Invasion.
    Anticancer Res. 2017;37:4311-4318.
    PubMed     Abstract available


  140. LIN C, Wang J, Wang Y, Zhu P, et al
    GRP78 Participates in PCA3-regulated Prostate Cancer Progression.
    Anticancer Res. 2017;37:4303-4310.
    PubMed     Abstract available


  141. SOBKOWICZ AD, Sanders AJ, Mason MD, Jiang WG, et al
    Potential Implication of Paxillin in Cancer Establishment Within the Bone Environment.
    Anticancer Res. 2017;37:4255-4268.
    PubMed     Abstract available


  142. HUNG SC, Yang CK, Cheng CL, Ou YC, et al
    Long-term Oncologic Outcomes of Robotic-assisted Radical Prostatectomy by a Single Surgeon.
    Anticancer Res. 2017;37:4157-4164.
    PubMed     Abstract available


    July 2017
  143. DETTI B, D'Angelillo RM, Ingrosso G, Olmetto E, et al
    Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy.
    Anticancer Res. 2017;37:3717-3722.
    PubMed     Abstract available


  144. MIYAZAWA Y, Takahiro S, Yoshitaka S, Nomura M, et al
    Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab.
    Anticancer Res. 2017;37:3667-3671.
    PubMed     Abstract available


  145. OZGUR E, Celik AI, Darendeliler E, Gezer U, et al
    PCA3 Silencing Sensitizes Prostate Cancer Cells to Enzalutamide-mediated Androgen Receptor Blockade.
    Anticancer Res. 2017;37:3631-3637.
    PubMed     Abstract available


  146. WINTERS B, Brown L, Coleman I, Nguyen H, et al
    Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279.
    Anticancer Res. 2017;37:3385-3396.
    PubMed     Abstract available


    June 2017
  147. HU JC, Hung SC, Ou YC
    Assessments of Neoadjuvant Hormone Therapy Followed by Robotic-Assisted Radical Prostatectomy for Intermediate- and High-Risk Prostate Cancer.
    Anticancer Res. 2017;37:3143-3150.
    PubMed     Abstract available


  148. HONDA M, Yogosawa S, Kamada M, Kamata Y, et al
    A Novel Near-infrared Fluorescent Protein, iRFP720, Facilitates Transcriptional Profiling of Prostate Cancer Bone Metastasis in Mice.
    Anticancer Res. 2017;37:3009-3013.
    PubMed     Abstract available


  149. FITZPATRICK C, Lynch O, Marignol L
    68Ga-PSMA-PET/CT Has a Role in Detecting Prostate Cancer Lesions in Patients with Recurrent Disease.
    Anticancer Res. 2017;37:2753-2760.
    PubMed     Abstract available


  150. PEPE P, Garufi A, Priolo GD, Pennisi M, et al
    Multiparametric MRI/TRUS Fusion Prostate Biopsy: Advantages of a Transperineal Approach.
    Anticancer Res. 2017;37:3291-3294.
    PubMed     Abstract available


  151. KRUCK S, Hennenlotter J, Amend B, Geiger M, et al
    Chronic Periodontitis Does Not Impact Serum Levels of Prostate-specific Antigen.
    Anticancer Res. 2017;37:3163-3167.
    PubMed     Abstract available


    April 2017
  152. JOHANSSON AK, Lennernas B, Isacsson U
    Neurovascular Bundle Infiltration Can Explain Local Relapses Using Conformal Radiotherapy of Prostate Cancer.
    Anticancer Res. 2017;37:1825-1830.
    PubMed     Abstract available


  153. PARK J, Joung JY, Hwang JE, Hong D, et al
    Ninjurin1 Is Up-regulated in Circulating Prostate Tumor Cells and Plays a Critical Role in Prostate Cancer Cell Motility.
    Anticancer Res. 2017;37:1687-1696.
    PubMed     Abstract available


  154. MABUCHI M, Ueda M, Yoshida Y, Horiike K, et al
    Systematic Trial for Evaluating Docetaxel in a Human Prostate Cancer Cell DU145 Xenograft Model.
    Anticancer Res. 2017;37:1665-1676.
    PubMed     Abstract available


  155. OU YC, Hung SC, Hwang LH, Yang CK, et al
    Salvage Robotic-assisted Laparoscopic Radical Prostatectomy: Experience with 14 Cases.
    Anticancer Res. 2017;37:2045-2050.
    PubMed     Abstract available


    March 2017
  156. CICERO G, DE Luca R, Dorangricchia P, Dieli F, et al
    The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study.
    Anticancer Res. 2017;37:1475-1480.
    PubMed     Abstract available


  157. PALUMBO I, Matrone F, Montesi G, Bellavita R, et al
    Statins Protect Against Acute RT-related Rectal Toxicity in Patients with Prostate Cancer: An Observational Prospective Study.
    Anticancer Res. 2017;37:1453-1457.
    PubMed     Abstract available


  158. HENKENBERENS C, VON Klot CA, Ross TL, Bengel FM, et al
    68Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy.
    Anticancer Res. 2017;37:1273-1279.
    PubMed     Abstract available


  159. SCIALPI M, Prosperi E, D'Andrea A, Martorana E, et al
    Biparametric versus Multiparametric MRI with Non-endorectal Coil at 3T in the Detection and Localization of Prostate Cancer.
    Anticancer Res. 2017;37:1263-1271.
    PubMed     Abstract available


  160. ELLIS-CALEO T, Hegde JV, Bath S, Mesko S, et al
    Imaging and Pathology Correlations for Different Risk Stratification Models for Intermediate-risk Prostate Cancer.
    Anticancer Res. 2017;37:1237-1242.
    PubMed     Abstract available


  161. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Anticancer Res. 2017;37:1501-1505.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: